Market Overview

OXiGENE Says Phase 2 Data on ZYBRESTAT May Produce Transient Cut

Related OXGN
OXiGENE Reports Commencement of Phase 2 Study of Fosbretabulin
Events for the Week of Sept. 8-12

OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation today of data from a Phase 2 trial of ZYBRESTAT (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), a degenerative eye disease.

Posted-In: News FDA

 

Related Articles (OXGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional